HC Wainwright Issues Positive Outlook for Alkermes Earnings

Key Points

• HC Wainwright raised its Q3 2025 earnings estimate for Alkermes to $0.31 per share, a modest increase from the previous estimate of $0.30.
• Alkermes reported earnings of $0.52 EPS for the last quarter, exceeding expectations of $0.42 EPS, while revenue reached $390.66 million compared to forecasts of $343.20 million.
• Current analyst ratings show a consensus of "Moderate Buy" with an average price target of $41.08, featuring nine buy ratings and one strong buy rating.

Alkermes plc (NASDAQ:ALKS - Free Report) - Analysts at HC Wainwright upped their Q3 2025 EPS estimates for shares of Alkermes in a research note issued to investors on Wednesday, July 30th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $0.31 for the quarter, up from their prior forecast of $0.30. HC Wainwright has a "Neutral" rating and a $46.00 price target on the stock. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. HC Wainwright also issued estimates for Alkermes' Q4 2025 earnings at $0.40 EPS, FY2025 earnings at $1.47 EPS, Q2 2026 earnings at $0.27 EPS, Q4 2026 earnings at $0.39 EPS and FY2026 earnings at $1.22 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.42 by $0.10. Alkermes had a net margin of 23.15% and a return on equity of 24.86%. The business had revenue of $390.66 million during the quarter, compared to analyst estimates of $343.20 million. During the same period in the prior year, the business posted $1.16 earnings per share. The company's revenue was down 2.1% on a year-over-year basis.

ALKS has been the topic of several other research reports. UBS Group raised shares of Alkermes from a "neutral" rating to a "buy" rating and raised their price objective for the company from $33.00 to $42.00 in a research note on Tuesday, June 17th. Royal Bank Of Canada increased their price target on shares of Alkermes from $40.00 to $42.00 and gave the company a "sector perform" rating in a research note on Wednesday, July 30th. Cantor Fitzgerald raised shares of Alkermes to a "strong-buy" rating in a research note on Tuesday, May 13th. Needham & Company LLC reissued a "buy" rating and set a $45.00 target price on shares of Alkermes in a report on Tuesday, July 29th. Finally, Robert W. Baird upped their target price on Alkermes from $38.00 to $41.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Three research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $41.08.

Alkermes Price Performance

Alkermes stock traded down $0.28 during trading hours on Monday, reaching $26.27. The stock had a trading volume of 411,860 shares, compared to its average volume of 1,785,393. Alkermes has a 52 week low of $25.56 and a 52 week high of $36.45. The business's 50 day moving average price is $29.09 and its 200-day moving average price is $30.74. The company has a market cap of $4.34 billion, a price-to-earnings ratio of 12.65, a PEG ratio of 1.52 and a beta of 0.47.

Institutional Investors Weigh In On Alkermes

Several hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its position in Alkermes by 488.6% in the first quarter. JPMorgan Chase & Co. now owns 5,234,995 shares of the company's stock worth $172,860,000 after purchasing an additional 4,345,523 shares during the period. Avoro Capital Advisors LLC acquired a new stake in shares of Alkermes during the 4th quarter worth approximately $70,462,000. Nuveen LLC bought a new position in Alkermes in the 1st quarter worth approximately $66,689,000. RTW Investments LP increased its stake in Alkermes by 13.6% in the fourth quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock valued at $217,363,000 after purchasing an additional 903,802 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in shares of Alkermes by 109.5% in the 4th quarter. Nuveen Asset Management LLC now owns 1,659,821 shares of the company's stock valued at $47,736,000 after acquiring an additional 867,492 shares in the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Christian Todd Nichols sold 3,334 shares of the business's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total transaction of $103,654.06. Following the completion of the sale, the senior vice president owned 86,208 shares in the company, valued at $2,680,206.72. The trade was a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.40% of the stock is owned by company insiders.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.